Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)-Reference-Cited by-同舟云学术

Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)

Published:2018-08-16 Issue:19 Volume:61 Page:8597-8612
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Fensome Andrew¹^ORCID,Ambler Catherine M.²,Arnold Eric²,Banker Mary Ellen²,Brown Matthew F.²,Chrencik Jill²,Clark James D.³,Dowty Martin E.¹,Efremov Ivan V.¹,Flick Andrew²,Gerstenberger Brian S.¹,Gopalsamy Ariamala¹,Hayward Matthew M.²,Hegen Martin³,Hollingshead Brett D.⁴,Jussif Jason³,Knafels John D.²,Limburg David C.²,Lin David²,Lin Tsung H.³,Pierce Betsy S.²,Saiah Eddine¹,Sharma Raman²,Symanowicz Peter T.³,Telliez Jean-Baptiste³,Trujillo John I.²,Vajdos Felix F.²,Vincent Fabien²,Wan Zhao-Kui¹,Xing Li¹,Yang Xiaojing¹,Yang Xin²,Zhang Liying¹

Affiliation:

1. Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States

2. Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States

3. Inflammation and Immunology, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States

4. Drug Safety Research and Development, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States

Funder

Pfizer

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00917

Reference43 articles.

1. Cytokine receptor signaling through the Jak–Stat–Socs pathway in disease

2. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

3. Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

4. Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

5. Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases

Cited by 134 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concise synthesis of pyridopyridazines;Tetrahedron Letters;2024-10

2. Risk of nonmelanoma skin cancer in patients taking Janus kinase inhibitors for inflammatory bowel disease: A systematic review and meta-analysis;Dermatologica Sinica;2024-09-04

3. Inhibition of the Janus kinase protein (JAK1) by the A. Pyrethrum Root Extract for the treatment of Vitiligo pathology. Design, Molecular Docking, ADME-Tox, MD Simulation, and in-silico investigation;Computers in Biology and Medicine;2024-09

4. Januskinaseinhibitoren für dermatologische Erkrankungen;Die Dermatologie;2024-08-30

5. Validation of the Peak Pruritus‐Numerical Rating Scale in patients with chronic plaque psoriasis: results from a phase 2 study;International Journal of Dermatology;2024-08-19